Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Supplementation with cholecalciferol 1,000 IU/day during pregnancy is associated with greater offspring bone mineral density ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

HEALTH LITERACY: Understanding osteoporosis: Causes, risk factors, and preventive strategies for bone health ...

Lung transplant patients should undergo annual bone health screenings using dual-energy X-ray absorptiometry for the first ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Research indicates that vitamin D supplementation during pregnancy positively impacts children's bone health and lean mass, ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...